Recombinant Protein Production News and Research

RSS

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

18 Dec 2025

FUJIFILM Biosciences introduces BalanCD HEK293 perfusion a medium to enable gene therapy production

FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A.

15 Sep 2025

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Sino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AI

Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology.

From Sino Biological Inc. 12 Sep 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

From Sino Biological Inc. 7 Jun 2024

SPOC Proteomics announces new product launch at SLAS2024

SPOC Proteomics, Inc, a deep-tech life sciences company based out of Scottsdale Arizona (HQ) and Menlo Park California, announced the commercial launch of their customizable sensor-integrated proteome on chip (SPOC®) biosensors for limited beta testing at SLAS2024.

From SPOC Proteomics 7 Feb 2024

Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins

In a joint effort to provide lower cost and more defined reagents and media to the cell and gene therapy market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, has signed a manufacturing, distribution, and collaboration agreement with Core Biogenesis, an innovator in the field of recombinant human proteins expressed in plants.

From Nucleus Biologics 24 Jan 2024

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

In this Interview, Dr. Fang-Yi Chu talks to NewsMed about the role of transmembrane proteins in targeting oncology research.

From Sino Biological Inc. 23 Nov 2023

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

From Sino Biological Inc. 24 Oct 2023

Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing

Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

From Sino Biological Inc. 9 Oct 2023

Innovations in baculovirus–insect cell expression systems

The baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)— remains a crucial technology for manufacturing large and complex proteins. This eukaryotic expression system offers inherent safety, ease of scale-up, flexible product design, and versatility for a broad range of proteins.

From Sino Biological Inc. 20 Sep 2023

Difficult transmembrane protein targets for therapeutic antibodies

In this interview, News-Medical talks to Sylvia Xie, product scientist at Sino Biological, about the ongoing emergence of transmembrane proteins as targets for therapeutic antibodies.

From Sino Biological Inc. 12 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Advancing the development of vaccines through recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng, the head of CRO at Sino Biological, about current developments in the field of vaccine development through recombinant techniques.

From Sino Biological Inc. 4 May 2023

Sino Biological announces construction of its new US-based center for bioprocessing

Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

From Sino Biological Inc. 24 Nov 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Developing and manufacturing custom recombinant antibodies for R&D

In this interview, Dr. Linlin Zhang, technical specialist for Sino Biological Europe, discusses how Sino is expanding its product offerings into the European market and outlines its process for developing and manufacturing custom recombinant antibodies for their clients.

From Sino Biological Inc. 6 Apr 2022